KRAS Wild Type Protein, Human, Recombinant, Biotinylated, GppNHp-Loaded

N-terminal AviTag™, N-terminal 8XHis

High-purity KRAS Wild Type protein supplied in a defined GppNHp-loaded active-state conformation for controlled biochemical workflows, including SPR, BLI, ELISA, pull-down, AlphaScreen, MST, effector binding assays, nucleotide-state-dependent inhibitor profiling, and oncology drug discovery applications.

Available Sizes

0.05 mg
$ 550.00
0.1 mg
$ 800.00
1.0 mg
$ 6,000.00

Ships with Certificate of Analysis (CoA)

Product Overview

Active GTP-bound KRAS WT is the physiologically relevant signaling form of RAS and the reference state for all effector interaction studies. While oncogenic mutants mimic constitutively active KRAS by impairing GTP hydrolysis, the cleanest biochemical tool for studying active-state KRAS biology remains WT KRAS loaded with a non-hydrolyzable GTP analogue such as GppNHp.

This product provides recombinant human KRAS WT (isoform KRAS4B, aa 1–185) loaded with GppNHp and site-specifically biotinylated at the N-terminal AviTag™. The GppNHp-loaded WT protein provides the highest-affinity binding to effectors such as RAF1-RBD, PI3K p110α-RBD, and RALGDS-RBD, making it the ideal positive control for all effector binding assay formats.

Because WT KRAS has intact GTPase activity, stable active-state KRAS WT can only be achieved with a non-hydrolyzable analogue such as GppNHp or GTPγS. This product uses GppNHp, which provides near-identical switch conformation to GTP-KRAS and is extensively characterized in published structural and biophysical literature.

Key Features

  • KRAS endogenous signaling control protein
  • Supplied pre-loaded with GppNHp
  • N-terminal AviTag™, N-terminal 8XHis tagged construct
  • Site-specifically biotinylated at the N-terminus
  • High purity recombinant protein
  • Optimized for binding assays
  • Research Use Only (RUO)

Applications

  • SPR
  • BLI
  • ELISA
  • Pull-down
  • AlphaScreen
  • MST
  • Effector binding assays
  • Nucleotide-state-dependent inhibitor profiling
  • Protein–protein interaction studies
  • Drug discovery workflows

Technical Notes

Why WT GppNHp is not equivalent to oncogenic mutant GppNHp

WT KRAS GppNHp and G12D KRAS GppNHp both adopt an active switch conformation, but their effector affinities and downstream signaling biases differ. WT KRAS GppNHp has the highest intrinsic GTPase rate (suppressed by GppNHp here), while G12D GppNHp mimics the constitutively active oncogenic state. Do not substitute one for the other in mechanistic studies — use both when characterizing a pan-RAS inhibitor.

GppNHp stability in storage

GppNHp is chemically stable in the storage buffer at -80°C. Unlike GTP, it does not hydrolyze during storage. Once thawed, the protein should be used within 24–48 hours or re-frozen. Do not add phosphatases to working buffers.

GppNHp vs. GTPγS vs. GTP

GppNHp (also written as GMPPNP) and GTPγS are both non-hydrolyzable GTP analogues used to lock KRAS in the active conformation. GppNHp replaces the bridging oxygen between β and γ phosphates with an imido nitrogen, preventing hydrolysis while maintaining a conformation nearly identical to GTP-bound KRAS. GTPγS substitutes a sulfur for the γ-phosphate oxygen and is slightly more reactive. For most inhibitor screening applications, GppNHp is preferred due to its greater chemical stability and the larger body of published KRAS structural data generated with this analogue. Using GTP directly is not practical for catalog supply due to hydrolysis during storage — the protein would lose activity during shipping and storage.

Biological Context & Applications

Protein Specifications

Gene KRAS
Mutation Wild-type
Nucleotide State GppNHp-Loaded
Organism Human
Tag N-terminal AviTag™, N-terminal 8XHis
Expression System E. coli
Purity >90% by Coomassie staining
Endotoxin <1 EU/mg
Biotinylated Yes
Oncogenic Status Wild Type
Assay Compatibility SPR, BLI, ELISA, Pull-down, AlphaScreen, MST, Effector binding assays, Nucleotide-state-dependent inhibitor profiling
UniProt ID P01116-2
Amino Acid Range 1-185
Buffer 20 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM MgCl2, 1 mM 2-mercapthoethanol, 10% glycerol
Storage -80 °C

Quality Control

  • Purity validated by SDS-PAGE
  • Identity confirmed by mass spectrometry
  • Assay compatibility verified
  • A Certificate of Analysis (CoA) is provided with every shipment

Ordering Information

Size Catalog No. Price Quote
0.05 mg KRAS-301-GPPNHP-005 $ 550.00 Request Quote
0.1 mg KRAS-301-GPPNHP-01 $ 800.00 Request Quote
1.0 mg KRAS-301-GPPNHP-1 $ 6,000.00 Request Quote
Need larger quantities or custom formats? We offer bulk pricing and custom production.
Request Bulk Quote

Typical response time: 1 business day

Custom Services

Need a different format, mutation, or production scale? We offer custom RAS protein engineering tailored to your research.

Custom Mutations

Alternative KRAS variants, including rare and novel mutations.

Tag & Labeling Options

His-tag, AviTag™, biotinylation, fluorescent labeling, or tag-free formats.

Scale-Up Production

From research-scale to bulk manufacturing for screening and preclinical work.

Protein Complexes

Complex formation such as KRAS–RAF-RBD and other binding partners.

Nucleotide Loading

Pre-load KRAS proteins with defined nucleotides, including GppNHp (non-hydrolyzable GTP analog) or GDP, for consistent assay-ready performance.

Tell us your mutation, format, or assay requirements and we’ll provide a tailored quote.

Request Custom Quote Email Us

Fast turnaround • Dedicated scientific support • Confidential projects

Related Products

Other KRAS mutants and formats available.

Research Use Only. Not for diagnostic or therapeutic use.